C]acetate into TCA-precipitable product, an indicator of fatty acid biosynthesis. Furthermore, it inhibited de novo fatty acid biosynthesis in this organism. In vitro, triclosan inhibited recombinant, purified S. aureus FabI with an IC 50 of approximately 1 µM. The combination of these biochemical and genetic data provide further evidence that the mode of action of triclosan in S. aureus is via inhibition of FabI.
Introduction
Triclosan (also know as Irgasan) is a broad-spectrum biocide that has been used for more than 30 years in toothpaste, cosmetics, antiseptic soaps, carpets and even toys. For many years, the mode of antibacterial action of triclosan was thought to be via non-specific disruption of the bacterial cell membrane. However, McMurry et al. 1 discovered that mutations in the enoyl-[acyl-carrier-protein (ACP)] reductase gene (fabI) of Escherichia coli gave rise to resistance to triclosan. FabI is one of the key enzymes in the bacterial fatty acid biosynthetic cycle. 2, 3 Furthermore, while triclosan selectively inhibited incorporation of radiolabelled acetate into fatty acids of logarithmically growing wild-type cells, it was significantly less effective at inhibiting acetate incorporation in the strain harbouring the mutant fabI gene. 1 These data are consistent with FabI being the antibacterial target of triclosan in E. coli.
Further work on E. coli by Heath et al. 4 illustrated that FabI was the target of both triclosan and a series of related 2-hydroxydiphenyl ethers. It was also shown that triclosan was a potent micromolar inhibitor of the wild-type FabI, whereas the mutated FabI protein that gave rise to triclosan resistance was less susceptible to inhibition by both triclosan and the other 2-hydroxydiphenyl ethers tested. Crystal structures have been solved for the E. coli FabI complexed with triclosan in the active site; these have provided a molecular mechanism for inhibition of E. coli FabI by triclosan. 4, 5 McMurry et al. 6 have also shown that mutations in the gene encoding InhA from Mycobacterium smegmatis gives rise to triclosan resistance. InhA is the mycobacterial homologue of E. coli FabI and thus the mode of antibacterial action of triclosan appears to be the same in both M. smegmatis and E. coli.
One of the best attributes of triclosan is its exceptional activity against staphylococci (MICs Ͻ 0.06 mg/L) including 
DNA manipulations
Standard DNA manipulations were performed as described previously. 9 Plasmid DNAs were purified from bacterial hosts using plasmid purification kits (Qiagen, Valencia, CA, USA) as directed by the manufacturer. For S. aureus, the protocol was modified by addition of lysostaphin (AMBI Technologies, Purchase, NY, USA) to a final concentration of 100 mg/L to the P1 buffer and incubating for 45 min at 37°C before the addition of the P2 buffer.
S. aureus RN4220 genomic DNA was isolated by pelleting 100 mL of an overnight culture and resuspending in 10 mL of GET (0.1 M glucose, 0.01 M EDTA and 0.05 M Tris-HCl pH 8) buffer containing 300 L of a 1 mg/mL stock of lysostaphin and 10 L of a 100 mg/mL stock of RNase A. Following lysostaphin/RNase A treatment for 1 h at 37°C, 2 mL of a 20% SDS solution were added and incubation was continued for 30 min at 37°C until the solution became viscous. Sodium perchlorate (5 M) was added to a final concentration of 1 M, and the sample was extracted twice with phenol/chloroform/isoamyl alcohol (Gibco-BRL, Rockville, MD, USA). Precipitation of DNA from the aqueous phase was achieved by adding 2 volumes of 95% ethanol, mixing and centrifugation at 14 000 rpm for 30 min. The ethanol was decanted, the nucleic acid pellet was washed with 70% ethanol and the DNA collected by centrifugation. The DNA pellet was resuspended finally in 1 mL distilled, deionized water and stored at 4°C.
Cloning of the S. aureus RN4220 fabI gene
The oligonucleotide primers Fab1 (5Ј-GCGGGATCCTG-TTCCGCATGGAGATACAC-3Ј) and Fab2B (5Ј-GCGG-GATCCTGTAAGGACTAATTCTGTGG-3Ј) were used to amplify the fabI gene, including the putative fabI promoter region, from S. aureus RN4220 genomic DNA. These primers were constructed with BamHI sites (GGATCC) at their 5Ј ends for later manipulations. The resulting 1388 bp DNA fragment was PCR purified using the Qiagen PCR cleanup kit as directed by the manufacturer. The purified product was digested with BamHI (Gibco-BRL) and cloned into pCU1 at the BamHI site. Following introduction into E. coli DH10B, the resulting recombinant plasmids were screened for orientation of insert by diagnostic PCR and restriction enzyme digestion. The construct containing fabI in the sense orientation was denoted pCS06. Double-stranded sequencing of the insert using an ABI automated sequencer (PE Biosystems, Foster City, CA, USA) confirmed the expected nucleotide sequence.
The primers Fab3 (5Ј-GCGCCCGGGATAAGGAGT-TATCTTACATG-3Ј) and Fab2S (5Ј-GCGCCCGGGTG-TAAGGACTAATTCTGTGG-3Ј) were used to amplify the fabI gene lacking a promoter sequence from S. aureus RN4220 genomic DNA as described above. SmaI restriction sites (CCCGGG) were incorporated at the 5Ј ends of the primer sequences for later manipulations. The resulting 1018 bp DNA fragment was purified, digested with SmaI and cloned into pCU1 at the SmaI site. Following diagnostic PCR, a construct containing the fabI coding sequence in the sense orientation was identified and denoted pCS06A. Sequence confirmation was obtained as above.
Introduction of recombinant plasmids into S. aureus RN4220
pCU1, pCS06 and pCS06A were introduced into S. aureus RN4220 via electroporation as described previously by Kraemer & Iandolo. 10 Overexpression assay S. aureus strains RN4220, RN4220(pCU1), RN4220(pCS06) and RN4220(pCS06A) were used in the overexpression assay. A 96-well microtitre MIC format was used. Serial dilutions of antibiotics were made in TSB such that the range of concentrations in a final assay volume of 100 L was 8-0.006 mg/L. Antibiotics tested included triclosan (Ciba Geigy, Chapel Hill, NC, USA), tetracycline, penicillin G, erythromycin, neomycin (Sigma, St Louis, MO, USA), mupirocin (SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA) and ciprofloxicin (US Pharmacia, Peapack, NJ, USA). An overnight culture grown in TSB was diluted in fresh TSB to achieve a cell density of c. 2 ϫ 10 5 cfu/mL. Approximately 1 ϫ 10 5 cfu/mL (in a 50 L volume) was then added to the serially diluted antibiotics. The MIC was considered to be the concentration at which the antibiotic prevented turbidity in the well after 18 h at 37°C. Growth was independently measured spectrophotometrically, and at various time points biomass was precipitated in TCA, filtered and washed on glass fibre. The precursors are soluble in trichloroacetic acid (TCA) while the macromolecules they give rise to are not. Drug and radiolabel were added to start the experiment. Incorporated radioactivity was assayed in the form of TCA-precipitable counts per minute and data were expressed as percentage inhibition of incorporation compared with a drug-free control.
Macromolecular synthesis assay
To confirm that fatty acid biosynthesis was inhibited, experiments were performed in parallel to extract total lipid into chloroform/methanol, and fatty acid methyl esters (FAMEs) were prepared using a standard BF3-methanol derivatization, extracted with hexane and purified by TLC. 13 
Enzymic inhibition of S. aureus FabI by triclosan
Purified FabI was obtained as described previously. 14 Assays were carried out in half-area, 96-well microtitre plates using 50 L assay mixtures containing 100 mM sodium N-[2-acetamido]-iminodiacetic acid (NaADA), pH 6.5, 4% glycerol, 0.25 mM crotonoyl CoA, 1 mM NADH and an appropriate dilution of S. aureus FabI. The IC 50 of triclosan was measured using a concentration range of 0.01-10 M. The consumption of NADH was monitored for 20 min at 30°C by following the change in absorbance at 340 nm. Initial velocities were estimated from an exponential fit of the non-linear progress curves represented by the slope of the tangent at t 0 . The IC 50 was estimated from a non-linear fit of the initial velocities to a standard, fourparameter model using GraFit 4.0 (Erithacus Software, Surrey, UK) and is reported as the mean Ϯ S.D. of seven determinations.
Western immunoblotting and estimation of FabI abundance in S. aureus cells
A procedure described previously by Zhang et al. 15 was followed. Polyclonal rabbit antibody was generated using purified S. aureus FabI as antigen.
Results and discussion

Inhibition of FabI by triclosan
Heath et al. 16 recently reported the inhibitory activity, or IC 50 , of triclosan for S. aureus FabI to be c. 3 M. Independently and concurrently, these experiments were carried out as described in Materials and methods. The IC 50 of triclosan for S. aureus FabI was 0.976 Ϯ 0.162 M, indicating specific, targeted inhibition of FabI by triclosan in S. aureus, and providing further confirmation of the reported FabI activity in S. aureus.
Overexpression assay
The genetic characterization for the mode of action of triclosan was initiated by examining the MICs of triclosan for S. aureus that overexpressed the presumed target, FabI. The S. aureus RN4220 fabI gene including the putative promoter was amplified using the specific oligonucleotide primers Fab1 and Fab2, and cloned on the 4.6 kb multicopy, E. coli-S. aureus shuttle plasmid pCU1. The complementing amplification product encompassing the fabI gene product and lacking the upstream promoter region was prepared using the primers Fab3 and Fab2, and also cloned into pCU1. The recombinant plasmids were introduced into S. aureus RN4220 by electroporation. MICs of triclosan for the recombinant strains are shown in the Table. 3 The MICs were determined by a serial dilution method in brain-heart infusion or TSB media and were performed a minimum of three times.
b
Plasmid designations are as follows: pCU1, vector; pCSO6, pCU1 containing fabI with promoter; pCS06A, pCU1 containing a promoterless fabI. The wild-type strain is plasmid free.
The MIC of triclosan for S. aureus RN4220, expressing wild-type levels of FabI, was 0.06 mg/L. The MIC of triclosan for S. aureus RN4220 (pCS06), in which the copy number of FabI has been elevated via introduction of a multicopy plasmid leading to additional expression of wild-type FabI, was increased c. 30-fold over wild type, to 2 mg/L. Cells harbouring either pCU1 alone or the recombinant plasmid containing the amplicon lacking a promoter for fabI (pCS06A) did not show increased resistance to triclosan. These results are consistent with the observations of McMurry et al. 1 for E. coli, in which wild-type fabI expressed on a multicopy plasmid in E. coli increased the triclosan resistance of the host strain 16-to 32-fold.
In some Gram-negative organisms such as Pseudomonas aeruginosa and E. coli, resistance to triclosan can be attributed to efflux by the MexAB-OprM or AcrAB systems rather than to overexpression of FabI. 14, 17 The S. aureus plasmid-containing strains were exposed to other classes of antibacterial agents to rule out any general mechanism of resistance such as efflux. No significant differences in susceptibility were observed between the strains overexpressing FabI and the corresponding wild-type strain for a range of antibiotics of different modes of action (Table) . Thus, an increased MIC of triclosan was not due to an efflux mechanism in these strains. This also demonstrates that an overexpression system is a valid and selective method of testing a bacterial target's susceptibility to a drug, as the FabI-overexpressing strain did not show any alteration in susceptibilities to a panel of unrelated antibiotics with distinct modes of action.
Confirmation of protein levels
Expression levels of FabI in the wild-type and FabI overexpression strains were examined by quantitative Western immunoblotting (Figure 1 ). The abundance of FabI in S. aureus strain RN4220 grown to mid-log phase was determined to be c. 12 000 copies per cell (Figure 1, lane 3) . RN4220 containing the plasmid vector pCU1 had the same FabI levels as the host strain ( Figure 1, lane 4) , whereas the FabI-overexpressing strain RN4220(pCS06) produces approximately three-to four-fold more FabI (lane 5).
Macromolecular synthesis
To demonstrate that the primary mode of action of triclosan against S. aureus is via inhibition of fatty acid biosynthesis, exponentially growing S. aureus was incubated with radiolabelled macromolecular precursors of fatty acid biosynthesis, DNA replication, transcription, cell wall biosynthesis and translation, plus triclosan ( Figure 2 ). As expected from an inhibitor of fatty acid biosynthesis, inhibition of acetate incorporation was observed early (20 min post-labelling) and increased over time; the remainder of the macromolecular profiles remained unaffected.
As a comparison, the macromolecular profiles of tetracycline (a protein synthesis inhibitor) and ciprofloxacin (a DNA synthesis inhibitor) were also examined ( Figure 3) . The data illustrate that triclosan selectively and rapidly inhibits acetate incorporation. The data collected at the 20 min time point were representative of the data collected from 5 to 40 min. Furthermore, analysis of the FAMEs at each time point confirmed that triclosan, but not ciprofloxacin or tetracycline, inhibited de novo fatty acid biosynthesis.
These results are similar to the selective inhibition of acetate incorporation observed with triclosan against E. coli. 18 However, a higher concentration (1 versus 30 mg/L) was required to achieve c. 70% inhibition of acetate incorporation in E. coli, presumably because triclosan exhibits greater antibacterial activity against S. aureus than against E. coli. Therefore, the selective inhibition of fatty acid biosynthesis in S. aureus by triclosan further illustrates that FabI is the antibacterial target in this organism.
Figure 1.
Western immunoblotting analysis using anti-FabI antibody. Lanes 1 and 2, purified S. aureus FabI at 10 ng and 1 ng, respectively; lane 3, RN4220; lane 4, RN4220(pCU1); lane 5, RN4220(pCS06). Cells were grown to mid-log phase and samples were collected and assayed. Polyclonal rabbit anti-FabI antibody and HRP-conjugated goat anti-rabbit IgG (Sigma) were used at 1:1000 and 1:20 000 dilutions, respectively. In conclusion, the combination of these data provide further biochemical and genetic characterization of both the mode of action of triclosan against S. aureus and the enoyl ACP reductase from this organism. Macromolecular synthesis was carried out as described in Materials and methods in S. aureus RN4220 at 20 min using sub-inhibitory levels of (a) triclosan, (b) ciprofloxacin and (c) tetracycline. Per cent inhibition is determined by comparison with non-drug-treated control. Experiments are an average of two independent measurements and the error bars indicate standard deviation from the mean.
